Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

26.92 1.66

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

26.22

Maximum

27.1

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+48.53% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

805M

2.9B

Előző nyitás

25.26

Előző zárás

26.92

Hangulat hírek alapján

By Acuity

34%

66%

91 / 339 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 3. 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

2026. szept. 3. 23:56 UTC

News
Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

2026. szept. 3. 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

2026. szept. 3. 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

2026. szept. 3. 23:51 UTC

News
Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

2026. szept. 3. 23:51 UTC

News
Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

2026. szept. 3. 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

2026. szept. 3. 23:46 UTC

News
Social Media

Hewlett Packard Enterprise shares are lower in after-market trading, despite strong networking revenue guidance and broader market gains ahead of employment data.

2026. szept. 3. 23:41 UTC

News

JP Morgan upgrades CPRT to Overweight, raises target to $40 after-market.

2026. szept. 3. 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2026. szept. 3. 23:36 UTC

News

Ulta Beauty will participate in a Fireside Chat at the Barclays Global Consumer Conference on September 10, 2026. Shares are higher in after-market trading.

2026. szept. 3. 23:31 UTC

News

Honeywell International Inc shares are lower in after-hours trading, despite broader market gains. The stock is near the lower end of its one-month range.

2026. szept. 3. 23:26 UTC

News

Jefferies maintained a Buy rating on Five Below and raised its price target to $420. Shares are trading higher in after-market hours following the updates.

2026. szept. 3. 23:21 UTC

News
Social Media

Meta Platforms Inc. shares are higher in after-market hours, supported by a Buy rating from Bank of America with a price target of $810.

2026. szept. 3. 23:21 UTC

News

Thermo Fisher Scientific shares are lower in after-market hours despite CLSA initiating coverage with an Outperform rating and a $748 price target.

2026. szept. 3. 23:11 UTC

News

Ethereum is trading higher during Thursday's session, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 3. 23:11 UTC

News

Ethereum is trading higher today, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026. szept. 3. 23:05 UTC

News

USD/HKD trades roughly flat amid stable market activity. An increase in USDE supply to $4.26 billion may influence dynamics but has not impacted prices today.

2026. szept. 3. 23:05 UTC

News

WEX Inc. shares decline in after-market hours despite announcing an integration with Driivz Ltd. for electric vehicle charging solutions, with a fair value of $187.30.

2026. szept. 3. 23:05 UTC

Correlated Moves
News

Elastic NV plans to integrate OpenAI GPT cyber models into its Elastic Security platform, enhancing security capabilities. Shares are trading roughly flat in after-market hours.

2026. szept. 3. 23:05 UTC

Macro Event
Correlated Moves
News

The USD/PLN exchange rate is declining amid mixed U.S. jobless claims data, with initial claims rising slightly above expectations.

2026. szept. 3. 23:02 UTC

News
Social Media

Lululemon Athletica reported second-quarter revenue of $2.42 billion, below estimates. The stock fell sharply in after-market hours, reaching its lowest level since May 2018.

2026. szept. 3. 23:02 UTC

News
Correlated Moves
Social Media

DocuSign shares rise in after-market trading following strong fiscal Q2 results and raised revenue guidance, despite earlier pulling back from a session high.

2026. szept. 3. 23:01 UTC

News

PulteGroup Inc shares are higher in after-market hours following a Buy rating from StoneX analyst Michael, who set a price target of $148.00.

2026. szept. 3. 23:01 UTC

News

eGain Corp shares are lower in after-market trading following disappointing fiscal 2027 guidance, despite reporting revenue and adjusted EPS that exceeded estimates.

2026. szept. 3. 23:01 UTC

News

Concrete Pumping Holdings reported strong Q3 results, raising revenue guidance and announcing a quarterly dividend, driving shares higher in after-market trading.

2026. szept. 3. 23:01 UTC

News
Social Media
Event

UiPath Inc shares declined in after-market hours despite reporting second-quarter revenue of $410 million and raising its fiscal year 2027 outlook.

2026. szept. 3. 23:01 UTC

News
Event

Oxford Industries reports second-quarter sales of $394 million and lowers full-year adjusted EPS guidance to $1.60-$2.00, leading shares lower in after-market hours.

2026. szept. 3. 23:01 UTC

News
Social Media

Strategy Inc shares declined after hours, retracing from earlier gains amid social media discussions and news from Iran affecting sentiment.

2026. szept. 3. 23:01 UTC

News
Event
Social Media

Smith & Wesson Brands reported strong Q1 results, with net sales of $112.6 million and adjusted EPS of $0.06, boosting shares in after-market trading.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

48.53% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 39.33 USD  48.53%

Magas 45 USD

Alacsony 36 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

3

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

91 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat